BR112017000640A2 - anticorpos neutralizantes do vírus influenza b e suas utilizações - Google Patents

anticorpos neutralizantes do vírus influenza b e suas utilizações

Info

Publication number
BR112017000640A2
BR112017000640A2 BR112017000640A BR112017000640A BR112017000640A2 BR 112017000640 A2 BR112017000640 A2 BR 112017000640A2 BR 112017000640 A BR112017000640 A BR 112017000640A BR 112017000640 A BR112017000640 A BR 112017000640A BR 112017000640 A2 BR112017000640 A2 BR 112017000640A2
Authority
BR
Brazil
Prior art keywords
virus
influenza
neutralizing antibodies
binding
antigen
Prior art date
Application number
BR112017000640A
Other languages
English (en)
Portuguese (pt)
Inventor
Yuan Andy
Lanzavecchia Antonio
Corti Davide
BENJAMIN Ebony
Mary Mcauliffe Josephine
Wachter Leslie
Kallewaard-Lelay Nicole
Zhu Qing
Original Assignee
Lanzavecchia Antonio
Corti Davide
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanzavecchia Antonio, Corti Davide, Medimmune Llc filed Critical Lanzavecchia Antonio
Publication of BR112017000640A2 publication Critical patent/BR112017000640A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112017000640A 2014-07-15 2015-07-14 anticorpos neutralizantes do vírus influenza b e suas utilizações BR112017000640A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462024804P 2014-07-15 2014-07-15
PCT/US2015/040385 WO2016011035A2 (en) 2014-07-15 2015-07-14 Neutralizing anti-influenza b antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112017000640A2 true BR112017000640A2 (pt) 2017-11-14

Family

ID=55079157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000640A BR112017000640A2 (pt) 2014-07-15 2015-07-14 anticorpos neutralizantes do vírus influenza b e suas utilizações

Country Status (10)

Country Link
US (6) US10294292B2 (enExample)
EP (1) EP3169407A4 (enExample)
JP (4) JP6837434B2 (enExample)
CN (4) CN106573154B (enExample)
AU (3) AU2015289805B2 (enExample)
BR (1) BR112017000640A2 (enExample)
CA (1) CA2954780A1 (enExample)
MX (3) MX392761B (enExample)
RU (2) RU2739952C2 (enExample)
WO (1) WO2016011035A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60938B1 (sr) * 2013-10-02 2020-11-30 Medimmune Llc Neutrališuća antitela na grip a i njihova upotreba
WO2016011035A2 (en) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
PT3303384T (pt) 2015-06-01 2021-10-14 Medimmune Llc Moléculas de ligação neutralizantes anti-influenza e suas utilizações
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
PH12022550963A1 (en) * 2019-10-28 2023-09-25 Regeneron Pharma Anti-hemagglutinin antibodies and methods of use thereof
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用
US20250320279A1 (en) * 2021-11-30 2025-10-16 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
CN118420751B (zh) * 2022-07-09 2025-04-08 东莞市朋志生物科技有限公司 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6071251A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
WO2000059932A1 (fr) * 1999-03-31 2000-10-12 Otsuka Pharmaceutical Co., Ltd. Peptides se liant a l'hemagglutinine du virus de la grippe
JP4656478B2 (ja) 2000-02-22 2011-03-23 株式会社医学生物学研究所 抗体ライブラリー
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
AU2003251809A1 (en) 2002-07-11 2004-02-02 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005007697A1 (ja) 2003-07-23 2005-01-27 Fujirebio Inc. 抗インフルエンザａ型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具
CN103446582A (zh) 2003-08-11 2013-12-18 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
NZ598048A (en) 2006-01-17 2013-05-31 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of n-glycans in plants
AU2007226856A1 (en) 2006-03-21 2007-09-27 Michael Rynkiewicz Methods for humanizing antibodies and humanized antibodies made thereby
WO2007117577A2 (en) 2006-04-07 2007-10-18 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-18 receptor
US20080014205A1 (en) 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
PL2069403T3 (pl) 2006-10-02 2015-08-31 Regeneron Pharma Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
JP5601836B2 (ja) 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド Ｔｅｓ７およびｔｅｓ７に結合する抗体
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP2125886A2 (en) 2007-03-13 2009-12-02 Humabs LLC Antibodies against h5n1 strains of influenza a virus
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
RU2553325C2 (ru) * 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
AU2011344126B2 (en) 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
MX352338B (es) 2011-07-18 2017-11-17 Inst Res Biomedicine Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
AU2012312529B2 (en) 2011-09-20 2018-01-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
CA2861515A1 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US8834881B2 (en) * 2012-03-08 2014-09-16 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
BR112015010817A8 (pt) * 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
RS60938B1 (sr) 2013-10-02 2020-11-30 Medimmune Llc Neutrališuća antitela na grip a i njihova upotreba
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
PT3303384T (pt) 2015-06-01 2021-10-14 Medimmune Llc Moléculas de ligação neutralizantes anti-influenza e suas utilizações
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂

Also Published As

Publication number Publication date
RU2017104638A3 (enExample) 2019-07-17
RU2711932C2 (ru) 2020-01-23
AU2024202231A1 (en) 2024-05-02
JP7209754B2 (ja) 2023-01-20
US20250263470A1 (en) 2025-08-21
MX2017000595A (es) 2017-10-12
CN119161468A (zh) 2024-12-20
CN106573154A (zh) 2017-04-19
JP2021074013A (ja) 2021-05-20
US11174304B2 (en) 2021-11-16
AU2015289805A1 (en) 2017-03-02
US10294292B2 (en) 2019-05-21
CN113563462B (zh) 2024-08-13
AU2020233635B2 (en) 2024-01-18
RU2017104638A (ru) 2018-08-15
JP2017523805A (ja) 2017-08-24
RU2020100073A (ru) 2020-03-03
JP2024069341A (ja) 2024-05-21
US20240076357A1 (en) 2024-03-07
US20220025020A1 (en) 2022-01-27
RU2020100073A3 (enExample) 2020-06-10
WO2016011035A8 (en) 2016-12-08
WO2016011035A2 (en) 2016-01-21
CA2954780A1 (en) 2016-01-21
MX2022006558A (es) 2022-07-11
AU2020233635A1 (en) 2020-10-08
RU2739952C2 (ru) 2020-12-30
US10519221B2 (en) 2019-12-31
CN113173990B (zh) 2024-10-29
JP6837434B2 (ja) 2021-03-03
US11787853B2 (en) 2023-10-17
MX392761B (es) 2025-03-21
EP3169407A4 (en) 2018-04-25
EP3169407A2 (en) 2017-05-24
US20190233504A1 (en) 2019-08-01
MX2022006561A (es) 2022-07-11
US20200190169A1 (en) 2020-06-18
WO2016011035A3 (en) 2016-03-10
US20170218054A1 (en) 2017-08-03
CN113563462A (zh) 2021-10-29
JP2023052268A (ja) 2023-04-11
AU2015289805B2 (en) 2020-06-25
JP7453430B2 (ja) 2024-03-19
US12325740B2 (en) 2025-06-10
CN106573154B (zh) 2021-06-15
CN113173990A (zh) 2021-07-27

Similar Documents

Publication Publication Date Title
BR112017000640A2 (pt) anticorpos neutralizantes do vírus influenza b e suas utilizações
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
MX382043B (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
CO2017007673A2 (es) Anticuerpos anti-cd47
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
MA43164A (fr) Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
BR112017009813A2 (pt) conjugados de anticorpo fármaco
BR112016017046A2 (pt) Anticorpos contra glicoproteína f de vírus hendra e nipah
MX2022001220A (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
BR112016018082A2 (pt) ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos?
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
MX2018002467A (es) Anticuerpos y ensayos para deteccion del antigeno leucocitico (cd37).
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112018072708A2 (pt) molécula de ácido nucleico, composição, e, método para tratar uma infecção por influenza em um sujeito.
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
BR112015017981A2 (pt) anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: MEDIMMUNE, LLC (US) ; DAVIDE CORTI (CH) ; ANTONIO LANZAVECCHIA (CH)

B25G Requested change of headquarter approved

Owner name: MEDIMMUNE, LLC (US) ; DAVIDE CORTI (CH) ; ANTONIO LANZAVECCHIA (CH)

B25A Requested transfer of rights approved

Owner name: MEDIMMUNE, LLC (US) ; ANTONIO LANZAVECCHIA (CH) ; HUMABS BIOMED SA (CH)

B25A Requested transfer of rights approved

Owner name: MEDIMMUNE, LLC (US) ; HUMABS BIOMED SA (CH) ; HUMABS BIOMED SA (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: MEDIMMUNE, LLC (US) ; HUMABS BIOMED SA (CH)

Free format text: RETIFICADO O DESPACHO 25.1 PUBLICADO NA RPI 2668 DE 22/02/2022 SOB O ITEM (71).

B09B Patent application refused [chapter 9.2 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023017738-0 PROTOCOLO 870230077639 EM 31/08/2023 19:11.

B12B Appeal against refusal [chapter 12.2 patent gazette]